SCHEMBL5642192

SCHEMBL5642192

C1=Nc2ccsc2CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4757718 0.70
SCHEMBL2925217 0.69
SCHEMBL3956654 0.64 PNMT (0.31)
SCHEMBL30220101 0.64
SCHEMBL8984087 0.61
SCHEMBL581338 0.59
SCHEMBL24783963 0.58 MEN1 (0.37)
SCHEMBL15120307 0.58 HTR5A (0.35)
SCHEMBL29904252 0.58
SCHEMBL14733941 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0452002-A2 Thienopyrimidine derivatives DOWELANCO (US) 1991-10-16 EP claimed
EP-0008408-B1 1,2,3,5-TETRAHYDROIMIDAZOTHIENOPYRIMIDIN-2-ONES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS DAIICHI SEIYAKU CO., LTD. (JP) 1981-12-09 EP claimed
WO-2026106929-A1 DIHYDROQUINAZOLINES USEFUL AS CYTOMEGALOVIRUS ANTIVIRAL AGENTS ASSEMBLY BIOSCIENCES, INC. (US) 2026-05-21 WO disclosed
EP-3753942-B1 CRYSTAL FORM OF 3,4-DIHYDROTHIENO[3,2-D]PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR PHAENO THERAPEUTICS CO LTD (CN) 2024-01-03 EP disclosed
EP-3753942-B1 CRYSTAL FORM OF 3,4-DIHYDROTHIENO[3,2-D]PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR PHAENO THERAPEUTICS CO LTD (CN) 2024-01-03 EP disclosed
US-11174270-B2 Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof PHAENO THERAPEUTICS CO., LTD. (CN) 2021-11-16 US disclosed
US-11174270-B2 Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof PHAENO THERAPEUTICS CO., LTD. (CN) 2021-11-16 US disclosed
US-11174270-B2 Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof PHAENO THERAPEUTICS CO., LTD. (CN) 2021-11-16 US disclosed
CN-111741960-B Crystal form of 3, 4-dihydrothieno [3,2-d ] pyrimidine compound and preparation method thereof 南京明德新药研发有限公司 2021-06-25 CN disclosed
CN-111741960-B Crystal form of 3, 4-dihydrothieno [3,2-d ] pyrimidine compound and preparation method thereof 南京明德新药研发有限公司 2021-06-25 CN disclosed
US-20210024538-A1 Crystal Form of 3,4-Dihydrothieno[3,2-D]Pyrimidine Compound and Preparation Method Thereof PHAENO THERAPEUTICS CO., LTD. (CN) 2021-01-28 US disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed
US-7285556-B2 Thienopyrimidine-based inhibitors of the src family BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) 2007-10-23 US disclosed
US-20040077663-A1 Thienopyrimidine-based inhibitors of the src family NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-04-22 US disclosed
EP-0452002-A2 Thienopyrimidine derivatives DOWELANCO (US) 1991-10-16 EP disclosed
EP-0008408-B1 1,2,3,5-TETRAHYDROIMIDAZOTHIENOPYRIMIDIN-2-ONES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS DAIICHI SEIYAKU CO., LTD. (JP) 1981-12-09 EP disclosed